Celgene sticks with the combo

Celgene a contrarian on chairman-CEO

While the market showed relative indifference to the appointment of CEO Mark Alles to the additional role of chairman of Celgene Corp. (NASDAQ:CELG), it goes against the trend among the big biotechs.

On Jan. 29 Celgene announced that Alles will become chairman effective Feb. 5

Read the full 441 word article

User Sign In